Baricitinib demonstrates superiority to adalimumab in rheumatoid arthritis
Lilly and Incyte have announced positive topline results from the fourth successful Phase 3 study (RA-BEAM ) of baricitinib.
List view / Grid view
News
BioTek introduces Synergy Neo2 high performance Multi-Mode Microplate Reader
14 October 2015 | By BioTek
BioTek introduces Synergy Neo2 high performance Multi-Mode Microplate Reader...
Merck relaunches its brand identity
14 October 2015 | By Victoria White
Merck says that the fundamental revision of the visual appearance as well as the introduction of a new logo reflect its transformation into a global science and technology company...
Piramal delivers its review of the global injectables market
14 October 2015 | By Victoria White
The review indicates that the near-term growth prospects are highest across generics, small molecule injectables, and in contract services...
Quotient Clinical showcases Translational Pharmaceutics and RapidFACT at AAPS 2015
13 October 2015 | By Quotient Clinical
Quotient Clinical, the Translational Pharmaceutics® company, will be highlighting the benefits of its unique, integrated approach to formulation development, real-time adaptive manufacturing and clinical testing on booth 1662...
Incyte and Merck to investigate epacadostat and Keytruda in melanoma
13 October 2015 | By Victoria White
Preclinical evidence suggests that the combination of these two agents may lead to an enhanced anti-tumour immune response...
CPI and Arecor investigate compatibility of biologic medicines with product containers
13 October 2015 | By Victoria White
CPI and Arecor carried out the investigation with the hope of improving stability and shelf life throughout transportation and storage...
Tecan offers walkaway batch processing for the Spark™ 10M reader
13 October 2015 | By Tecan Trading AG
Tecan’s innovative Spark 10M multimode reader can now be combined with the company’s Connect™ microplate stacker to offer semi-automated batch processing of up to 50 assay plates...
FDA grants Fast Track designation to Shire’s Cinryze
13 October 2015 | By Victoria White
Cinryze is being studied as an adjunct treatment to Donor Specific Antibodies (DSA) reduction therapy in kidney transplant patients with acute antibody mediated rejection...
Daiichi Sankyo helps raise awareness of VTE and AF
13 October 2015 | By Daiichi Sankyo
Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms...
Data on Eisai’s eribulin and lenvatinib presented at DGHO
13 October 2015 | By Victoria White
Five abstracts have highlighted the use of Eisai’s eribulin and lenvatinib in rare cancers at the German Association of Hematology and Oncology Meeting...
Bowel cancer can be divided into four distinct diseases
13 October 2015 | By Victoria White
Researchers have shown the bowel cancer can be assigned into different "consensus molecular subtypes"...
Quotient Clinical CEO Mark Egerton a winner at UK EY Entrepreneur of the Year 2015 awards
13 October 2015 | By Quotient Clinical
Quotient Clinical has announced that CEO Mark Egerton has received an EY Entrepreneur of the Year® 2015 UK Award...
CPhI experts warn USA trade laws are too heavily in favour of big pharma
13 October 2015 | By Victoria White
The findings come from the third part of the CPhI Worldwide 2015 annual report (entitled: ‘Push-pull factors on growth’)...
Lilly discontinues development of evacetrapib due to insufficient efficacy
12 October 2015 | By Victoria White
Lilly has said that it will conclude studies of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease...
